JP2005527576A5 - - Google Patents

Download PDF

Info

Publication number
JP2005527576A5
JP2005527576A5 JP2003581776A JP2003581776A JP2005527576A5 JP 2005527576 A5 JP2005527576 A5 JP 2005527576A5 JP 2003581776 A JP2003581776 A JP 2003581776A JP 2003581776 A JP2003581776 A JP 2003581776A JP 2005527576 A5 JP2005527576 A5 JP 2005527576A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
pharmaceutically acceptable
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003581776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/009984 external-priority patent/WO2003084536A1/en
Publication of JP2005527576A publication Critical patent/JP2005527576A/ja
Publication of JP2005527576A5 publication Critical patent/JP2005527576A5/ja
Withdrawn legal-status Critical Current

Links

JP2003581776A 2002-04-04 2003-04-01 エポチロン化合物の経口投与 Withdrawn JP2005527576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37010402P 2002-04-04 2002-04-04
PCT/US2003/009984 WO2003084536A1 (en) 2002-04-04 2003-04-01 Oral administration of epothilones

Publications (2)

Publication Number Publication Date
JP2005527576A JP2005527576A (ja) 2005-09-15
JP2005527576A5 true JP2005527576A5 (enExample) 2006-05-25

Family

ID=28792029

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003581776A Withdrawn JP2005527576A (ja) 2002-04-04 2003-04-01 エポチロン化合物の経口投与

Country Status (9)

Country Link
US (1) US6936628B2 (enExample)
EP (1) EP1492529A1 (enExample)
JP (1) JP2005527576A (enExample)
AU (1) AU2003226189A1 (enExample)
IS (1) IS7481A (enExample)
NO (1) NO20044452L (enExample)
PL (1) PL372773A1 (enExample)
TW (1) TW200403994A (enExample)
WO (1) WO2003084536A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
EP1575487B1 (en) 2002-05-14 2019-08-14 DuPont Nutrition USA, Inc. Coattrited microcrystalline cellulose hydrocolloid compositions and method for manufacture
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
FR2878443B1 (fr) * 2004-08-03 2009-01-16 Promindus Actions Promotionnel Composition pharmaceutique, destinee a l'administration par voie orale de principe(s) actif(s) fortement gastro-labile(s et sa preparation
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1674098A1 (en) * 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
US20060255258A1 (en) * 2005-04-11 2006-11-16 Yongdong Wang Chromatographic and mass spectral date analysis
US7879382B2 (en) * 2005-09-30 2011-02-01 Fmc Corporation Stabilizers and compositions and products comprising same
JP5410290B2 (ja) * 2006-10-27 2014-02-05 エフ エム シー コーポレーション 共処理組成物とその製造方法、打錠可能な錠剤処方物、錠剤の製造方法及び錠剤
EP2009114A1 (en) * 2007-06-29 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
TW201129386A (en) 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TWI461213B (zh) 2009-11-05 2014-11-21 Fmc Corp 作為藥物賦形劑之微晶纖維素及磷酸鈣之組合物
US8632819B2 (en) * 2009-12-22 2014-01-21 Fmc Corporation Microcrystalline cellulose and calcium carbonate compositions useful as recompactible pharmaceutical excipients
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
JP6188030B2 (ja) 2011-10-05 2017-08-30 エフ エム シー コーポレーションFmc Corporation 微結晶セルロースおよびカルボキシメチルセルロースの安定化剤組成物、該組成物の製造方法並びに食品製品
EP2764045B1 (en) 2011-10-05 2017-03-01 FMC Corporation Stabilizer composition of co-attrited microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
EP2787836A4 (en) 2011-12-09 2015-05-27 Fmc Corp Inc TOGETHER DECOMMINATED STABILIZER COMPOSITION WITH INCREASED STRENGTH
GB2595203A (en) 2020-03-03 2021-11-24 Alkaloid Ad Skopje Formulation
CZ2020287A3 (cs) 2020-05-20 2021-12-01 Mendelova Univerzita V Brně Způsob přípravy nanokompozitního materiálu na bázi redukovaného grafen oxidu, dusičnanu stříbrného a octanu měďnatého, nanokompozitní materiál, přípravek jej obsahující a jeho použití
WO2022048592A1 (zh) * 2020-09-02 2022-03-10 北京华昊中天生物医药股份有限公司 优替德隆的固体口服制剂

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5671397A (en) * 1993-12-27 1997-09-23 At&T Global Information Solutions Company Sea-of-cells array of transistors
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
ES2206607T3 (es) 1995-11-17 2004-05-16 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Derivados de epotilones, preparacion y utilizacion.
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
HU229833B1 (en) 1996-11-18 2014-09-29 Biotechnolog Forschung Gmbh Epothilone d production process, and its use as cytostatic as well as phytosanitary agents
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
ATE221888T1 (de) 1997-02-25 2002-08-15 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
CA2286610C (en) 1997-04-18 2007-03-13 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
AU8542898A (en) 1997-07-16 1999-02-10 Schering Aktiengesellschaft Thiazole derivatives, method for their production and use
JP2001512723A (ja) 1997-08-09 2001-08-28 シエーリング アクチエンゲゼルシヤフト 新規エポチロン誘導体、その製法およびその薬学的使用
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
JP4644364B2 (ja) 1998-02-05 2011-03-02 ノバルティス アーゲー エポシロン組成物
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
AU758526B2 (en) 1998-02-25 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues therof
US6380395B1 (en) 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
HUP0200296A2 (en) 1998-12-23 2002-05-29 Bristol Myers Squibb Co Microbial transformation method for the preparation of an epothilone
AU3156700A (en) 1999-02-18 2000-09-04 Schering Aktiengesellschaft 16-halogen-epothilone derivatives, method for producing them and their pharmaceutical use
ATE254615T1 (de) 1999-02-22 2003-12-15 Biotechnolog Forschung Gmbh C-21 modifizierte epothilone
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
AR023792A1 (es) 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
NZ526871A (en) * 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
CA2438610A1 (en) 2001-02-20 2002-08-29 Francis Y. F. Lee Treatment of refractory tumors using epothilone derivatives
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
EE05417B1 (et) 2001-03-14 2011-06-15 Bristol-Myers Squibb Company Epotilooni analoogide ja kemoterapeutikumide kombinatsiooni kasutamine teraapias
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives

Similar Documents

Publication Publication Date Title
JP2005527576A5 (enExample)
JP6193922B2 (ja) ハロアルキルヘテロアリールベンズアミド化合物
RU2003126174A (ru) Фармацевтические дозированные формы эпотилона для перорального введения
JP2004529904A5 (enExample)
JP5837936B2 (ja) アルキルスルフィニル置換チアゾリド化合物
JP2004516314A5 (enExample)
JP2007524683A5 (enExample)
RU2003128312A (ru) Производные эпотилона, используемые для лечения резистентных опухлей
JP2003516987A5 (enExample)
WO2012144463A1 (ja) 腫瘍治療剤
CN107530352A (zh) 使用茚满乙酸衍生物治疗肝病的方法
AU2010208270B2 (en) Solid oral formulations of a pyridopyrimidinone
RU2002119016A (ru) N-[5-[[[5-алкил-2-оксазолил]метил]тио]-2-тиазолил]карбоксамидные ингибиторы циклин-зависимых киназ
JP2003502367A5 (enExample)
JP2002505276A (ja) 潰瘍用医薬組成物
JP5634862B2 (ja) 低粘度アントラサイクリン製剤
AR040077A1 (es) Composiciones farmaceuticas y metodos de uso de derivados de epotilona modificados por c-21
AU2003227702B2 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
EP2210643A3 (en) Combinations comprising epothilones and pharmaceutical uses thereof
TW200403059A (en) Combination of a reflux inhibitor and an imidazopyridine for the treatment of gerd
JP4781592B2 (ja) 胃食道逆流症の予防・治療剤
JP2009504746A (ja) 第Xa因子インヒビターのシクロデキストリン包接複合体
JP2006514063A5 (enExample)
JP2003507475A5 (enExample)
JP2007510653A5 (enExample)